Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for transthyretin amyloidosis with cardiomyopathy:
- Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (2025) NICE technology appraisal guidance 1121
- Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (2025) NICE technology appraisal guidance 1115
- Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (2024) NICE technology appraisal guidance 984
This page was last updated: